Literature DB >> 8408453

p53 mutations in all stages of thyroid carcinomas.

M Zou1, Y Shi, N R Farid.   

Abstract

The p53 gene has been implicated as a tumor suppressor gene whose inactivation by mutations has been noted in a variety of human malignancies. Using single strand conformation polymorphism analysis of cDNA fragments amplified by reverse transcription-polymerase chain reaction, we analyzed 57 thyroid tumor specimens (8 follicular adenomas and 49 carcinomas) for the presence of mutations in exons 5, 6, 7, and 8 of p53 gene. Twelve of 49 (24.5%) of the thyroid carcinomas tested presented a mutated p53 allele, but none of the 8 benign thyroid tumors did. Mutations were found in 1 of 5 anaplastic carcinomas and 11 of 44 differentiated carcinomas. Three of these 11 differentiated tumor specimens showed foci of solid tissue with evidence of dedifferentiation. Two samples (1 with anaplastic carcinoma, the other with papillary carcinoma) had double mutations on the same allele resulting in a frameshift. Most mutations were point mutations, and 50% of those were G:C to A:T transitions. Seventy-five percent of the mutations were in exons 7 and 8. The presence of p53 mutations was not associated with tumor stage or histological type. Our data suggest that p53 mutations are involved in thyroid carcinogenesis and may play an important role in the malignant transformation of thyroid cells as well as thyroid tumor progression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8408453     DOI: 10.1210/jcem.77.4.8408453

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  Predictors of thyroid tumor aggressiveness.

Authors:  O H Clark
Journal:  West J Med       Date:  1996-09

2.  Anaplastic thyroid cancer and hyperthyroidism.

Authors:  Vijay Kumar; Bruno Blanchon; Xin Gu; Marjorie Fowler; David Scarborough; Cherie Ann Nathan; Subhashini Yaturu
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

3.  Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21.

Authors:  K Y Lam; C Y Lo; K W Chan; K Y Wan
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

Review 4.  Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

Review 5.  P53 mutations in thyroid carcinoma: tidings from an old foe.

Authors:  N R Farid
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

6.  Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model.

Authors:  Patrick Shannon; Nesrin Sabha; Nelson Lau; Deepak Kamnasaran; David H Gutmann; Abhijit Guha
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

Review 7.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

8.  Absence of p53 mutation in Japanese patients with malignant thyroid lymphoma.

Authors:  K Iyota; K Takeda; F Matsuzuka; T Okabayashi; S Morita; K Kuma; K Hashimoto
Journal:  J Endocrinol Invest       Date:  1994-11       Impact factor: 4.256

9.  Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis.

Authors:  Eun-Woo Lee; Min-Sik Lee; Suzanne Camus; Jaewang Ghim; Mi-Ran Yang; Wonkyung Oh; Nam-Chul Ha; David P Lane; Jaewhan Song
Journal:  EMBO J       Date:  2009-06-18       Impact factor: 11.598

10.  Immunohistochemical Localization of p53 in Human Thyroid Neoplasms: Correlation with Biological Behavior.

Authors:  Sefik A. Hosal; Robyn L. Apel; Jeremy L. Freeman; Abbas Azadian; Irving B. Rosen; Virginia A. LiVolsi; Sylvia L. Asa
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.